Nanofiber technology in the ex vivo expansion of cord blood-derived hematopoietic stem cells

Nanomedicine : Nanotechnology, Biology, and Medicine
Mónica Sofia Ventura Ferreira, Seyed Hadi Mousavi

Abstract

Umbilical cord blood (CB) can be used as an alternative source of hematopoietic stem cells (HSCs) for transplantation in hematological and non-hematological disorders. Despite several recognized advantages the limited cell number in CB one unit still restricts its clinical use. The success of transplantation greatly depends on the levels of total nucleated cell and CD34+ cell counts. Thus, many ex vivo strategies have been developed within the last decade in order to solve this obstacle, with more or less success, mainly determined by the degree of difficulty related with maintaining HSCs self-renewal and stemness properties after long-term expansion. Different research groups have developed very promising and diverse CB-derived HSC expansion strategies using nanofiber scaffolds. Here we review the state-of-the-art of nanofiber technology-based CB-derived HSC expansion.

Citations

Mar 13, 2019·Soft Matter·Lei ChenLinge Wang
Sep 22, 2018·Current Opinion in Hematology·Melody Becnel, Elizabeth J Shpall
Jul 14, 2019·Gene Therapy·Amr M Al-Saif
Apr 5, 2021·Acta Biomaterialia·Chandralekha ChatterjeeCornelia Lee-Thedieck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.